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 EFFECTIVENESS OF NOVEL IMMUNOTHERAPY AND CHEMOTHERAPY 
TREATMENTS FOR FOLLICULAR AND DIFFUSE LARGE B-CELL 
LYMPHOMAS 
 
DMI?RIY BUTSENKO 
 
ABSTRACT  
The efficacy of therapeutic modalities for non-Hodgkin’s lymphoma have been tested 
and improved throughout the 19th century through various series of drug trials aimed at 
eliminating cellular malignancies, first through chemotherapy treatment, and more 
recently through immunotherapy. While to an extent successful in eliminating cancerous 
lesions and affected cells, chemotherapy treatments have shown to influence the 
induction of new malignancies, through genetic mutation, as well as unwanted toxic 
effects of systemic poisoning. The purpose of this thesis is to compare treatment methods 
in terms of their biomolecular activity, precision of intended results, and possible 
drawbacks, as well as their application to specific populations of Non-Hodgkin 
lymphoma diagnoses, including Follicular and Diffuse Large B-Cell lymphomas. In the 
following sections on contributing factors specific to Diffuse Large B-Cell lymphomas 
and Follicular lymphoma, elements of disease prognosis will be analyzed from a 
molecular and clinical point of view. This includes a focus on the impact of genetic 
mutation, the immunohistochemical evidence these changes present, as well as the 
variances in immune cell functionality, and finally a description of symptoms with 
iv 
 direction to specific underlying causes.  An analysis of standard of care chemotherapy, 
and monoclonal antibody treatments will then be provided for each occurrence.   
The second segment will discuss novel techniques being developed for the treatment of 
lymphoma including but not limited to new monoclonal antibodies, synthetic lethality 
modulation, inhibition of selected chemokine receptors, DNA vector immunization for 
production of internal host antibodies, concepts of cell mediated bispecific antibody 
induced destruction, and new generations of Immunomodulatory drugs. With the recent 
development of cost effective sequencing technology, included is a discussion of the shift 
towards personalized medicine treatments, targeting appropriate phenotypic specific 
populations for optimal results, as it relates to therapies for Diffuse Large B-Cell 
lymphoma and Follicular lymphoma. 
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 INTRODUCTION 
Beginning with the conception of the Rappaport classification in 1956, Non-Hodgkin 
lymphoma (NHL) has evolved to encompass cytological elements as well as genetic, 
clinical, and immunologic characteristics of disease. NHL presents itself in B-cell, T-cell, 
and Natural killer-cell lymphoma, with many distinct subtypes identified to date. The 
most prevalent NHL is that affecting B-cells, at an incidence rate of approximately 85%, 
of which Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) 
comprise more than half of cases (Lymphoma Research Foundation, 2010). NHLs are 
commonly associated with developed countries, and although unusual, sometimes 
aggregate in families, pointing to a genetic basis (Fisher and Fisher, 2004). Aside from a 
hereditary basis, factors like immunosuppression, radiation, cytogenetic viruses, bacteria, 
and various chemicals influence the mutagenic progression of NHL. While the 
heterogeneous etiology of NHL remains under study, there have been major 
breakthroughs in analysis of immunohistological and molecular means of malignancy.  
 
Determining diagnosis  
The Rappaport classification was the first system set in place to group homogenous 
patients according to their clinical and microscopic presentation. Rappaport proposed 
system for staging and diagnosing came from observing malignant cells that were either 
nodular or diffuse as well as identifying whether the disease affected lymphocytic or 
histiocytic cells (part of the mononuclear phagocytic family) (Garvin et al.,1980).  
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 2 
The process of B-cell maturation begins in the bone marrow with a hematopoietic stem 
cell following transformation to pro-B-cell, pre-B-cell, and finally immature B-cells, 
which are released into circulation to reach secondary lymphoid organs. It is in these 
lymph nodes that they gather, forming follicular centers where B-cells undergo somatic 
hypermutation and class switch to different immunoglobulins after activation by effector 
helper cells (NCCN.org, 2015). Throughout this process, the cells pick up various cell-
surface antigens, which are expressed and presented at different phases of the maturation 
cycle as shown in Figure 1. 
 
 
 
Figure 1. B-cell maturation process in primary and secondary lymphoid organs 
(Dalakas, 2008) 
 
FL derives its name from the location of its formation, which lies in the germinal centers 
of lymphatic organs, dense in B-cell population. It accounts for one third of NHL in 
adults (Solal-Celigny, et al., 2004). FL is a slower growing cancer as compared to 
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 DLBCL, but indolent FL can progress into DLBCL with treatment in approximately 30 
percent of patients, marking the importance of diagnosis at early stages (Thompson et al., 
2016). The identification of lymphadenopathy depends mainly on histopathological 
analysis of lymph node tissue obtained from either an excisional biopsy of lymph tissue 
and/or a bone marrow biopsy/aspiration. The presence of centroblasts and centrocytes in 
different concentrations allows the grading of the cancer as assigned by a pathologist. FL 
is confirmed by immunohistochemistry and flow cytometry. The typical 
immunophenotype for FL consists of CD10+, CD20+, BCL2+, BCL6+, cyclin D1-,  
CD5-, CD43- (King et al., 2000). Table 1summarize immunochemical marker panels for 
diagnosing FL: 
Table 1. Characterizing immunophenotypes in FL 
Immunochemistry panel for FL 
CD3 CD5 CD10  CD20 CD23 CD21 cyclin D1 CD43 BCL2* BCL6 
 
*Anti-apoptotic protein 
Flow cytometry panel for FL 
CD5 CD10 CD19 CD20 CD23 Kappa/lambda 
 
 
Patients with FL present with small to medium sized superficial and deep nodes or 
proliferation of mucosa-associated lymphoid tissue (MALT). This usually leads to 
increased gastrointestinal distress as the affected MALT grows in size, leading to partial 
obstructions of bowel (Salles, 2007). 
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 The genetic basis of FL formation is due primarily to the translocation of chromosomes 
14 and 18, resulting in the BCL2 rearrangement present in many cases of FL (Mahmoud 
and El-Sakhawy, 2011). BCL6 abnormalities may also be noted with FL. The 
dysregulation of these antiapoptotic proteins leads to the proliferations of nodular B-cells 
and the formation of tumor masses in patients. Without treatment, mutations in other 
proto-oncogenes will lead to transformation in about thirty percent of patients (Casulo et 
al., 2015) 
A recent study published in 2016 by Thompson et al., identifies two sets of specific 
microRNAs that are expressed differently between FL and DLBCL: miR-31 is highly 
expressed in FL and decreases as the lymphoma progresses, while miR-17-5p is noted to 
do the opposite. The data seems to indicate miRNA expression may be a useful indicator 
in gauging progression to higher grade lymphoma, and a target for potential therapies 
(Thompson et al., 2016) 
While the presentation of DLBCL is variable, the disease is identified by observing 
diffuse proliferation of large neoplastic B lymphoid cells through microscopic marrow 
analysis. Confirmation of disease occurs with the use of immunophenotyping and while 
this is adequate for diagnosis, flow cytometry may also be used to provide additional 
evidence. DLBCL presents itself generally with the immunophenotype CD20+, CD45+, 
CD3– (Anderson et al., 2009). Other markers may be used to identify various subtypes 
later discussed. Table 2 summarizes the panels for both immunophenotyping and flow 
cytometry. 
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 Table 2. Characterizing immunophenotypes in DLBCL 
EBER=Epstein-Barr encoding region; HHV8=human herpes virus 8. 
*Indicating possible cytogenetic viral causes of cell proliferation 
Immunochemistry panel for DLBCL 
CD20 CD3 CD5 CD10 CD45 Bcl-2 Bcl-6 Ki-67   MUM-1 MYC 
 
Flow cytometry panel for DLBCL 
Kappa/lambda CD45 CD3 CD5 CD19 CD10 CD20 
 
Additional IHC analysis to establish DLBCL subtype 
Cyclin/D1 CD30 CD138 EBER * ALK HHV8* SOX11 
Compiled from NCCN.org resources 
These markers and pathway proteins will be discussed as they relate to monoclonal 
antibody and chemotherapy in following sections. 
 
Clinical presentation 
The lab work necessary in assessing a case of DLBCL/FL includes serum lactate 
dehydrogenase levels (LDH), complete blood count (CBC) with differential, 
comprehensive metabolic panel, and uric acid levels. LDH has been useful in assessing 
physiological reactions to stress in many diseases and can be applied to analyze 
lymphoma growth, possibly determining risk of relapse (William et al., 2013).  
Splenic and liver dimensions should be assessed during physical examination, as well as 
performance status (PS) and the presence or absence of B-symptoms. B symptoms 
include the presence of fever, drenching night sweats, or unexplained weight loss. 
Drenching night sweats are very common in many lymphoma cases, yet their exact cause 
remains unknown. Doctors speculate it is a reaction to fever or ongoing inflammation 
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 (Dalland and Stanford, 1990). Lesions from this cancer are fast growing and can appear 
nodally or extranodally, possibly affecting lymph tissue in different quadrants of the 
body. 
The prognostic laboratory tests are very similar to DLBCL. Increased erythrocyte 
sedimentation rate, elevated LDH, elevated β2 microglobulin levels, lowered albumin 
levels, anemia, lymphocytopenia, and thrombocytopenia (Solal-Celigny et al., 2004) are 
indicators of either ongoing inflammation or signs of lymphoma infiltration. 
Recent genotyping technologies have allowed us to classify subtypes of DLBCL, adding 
possible central or peripheral nervous system involvement, and further classification of 
either activated B-cell (ABC) or germinal-center like (GCB) lymphomas. Even more 
recently a third, not yet fully activated b-cell classified categorization, has been added 
called T cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL) (Tirado et al., 2012).  
ABC is a more aggressive form of DLBCL as it affects mostly differentiating germinal 
B-cells that have been ‘activated’- being exposed to specific antigen, cytokine, or 
reciprocal activation from effector cells.  
The most common gene rearrangements in DLBCL are observed in the oncogene MYC, 
as well as regulatory proteins BCL2, and BCL6, at the 3q27 locus (Firedberg, 2008). 
Chromosomal translocations at t(14;18), t(3;v), t(8;14) observed by karyotyping and 
fluorescence in situ hybridization (FISH) are also known contributors to the pathogenesis 
of DLBCL (Frick et al., 2011). DLBCL known as ‘double hit’ is an aggressive cancer, 
caused by a rearrangement of at least two genes, affecting about 2- 11 percent of patients. 
The difference between the gene expression profiles of ABC and GCB lymphomas was 
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 demonstrated to be spectrally separated through genomic analysis. Figure 1 depicts this 
comparison as well as the survival rates for the subtypes ABC and GCB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- DNA methylation signatures for ABC and GCB diffuse large B-cell 
lymphomas and five year survival rates. A. Microarray methylation signature 
depicting encoded proteins found in B-cells of ABC and GCB subtype lymphomas: red 
indicating mutated phenotype, green indicating normal phenotype. B. Percent of overall 
survival and percent progression-free survival for red- ABC and blue- GCB subtypes 
(Shaknovich et al., 2010) 
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 The prospect of this classification provided the much needed analytical evidence to assess 
how each subtype responds to chemotherapy and immunotherapy treatments, paving the 
way for applications of personalized medicine in lymphoma. 
Failures of signaling genes in DNA repair pathways have been identified in these 
malignancies, giving rise to tumor cells that can escape apoptosis and thrive with gene 
expression plasticity. The following have been identified and are being studied as targets 
for future therapies and summarized below in Table 3. 
Table 3. Mutations in DNA repair and signaling mechanisms  
*Histone modification enzymes 
DNA repair and damage signaling genes in DLBCL  
TNFAIP3 CARD11 CD79A/B MyD88 TRAF2 TRAF3 
Epigenetic reprogramming DLBCL 
TET1 MLL2* EZH2* MEF2B EP300* CREBBP* 
Obtained from Camicia et al., 2015 
 
 
EZH2 is an important regulator of the GCB phenotype and with BCL6 is responsible for 
the formation of GCB DLBCL. The single replacement of tyrosine within EZH2 results 
in a gain of function, promoting an increased methylation of histone 3 (Shenand and 
Gascoyne, 2015). Altered function in the NF-κB pathway on the other hand, is a 
signature of most ABC DLBCL, leading to proliferative and resilient cancer cells. 
Figure 3 summarizes the most common genetic alterations in each subtype of DLBCL 
and whether or not this produces a gain or loss of function: 
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Figure 3. GCB and ABC-DLBCL pathogenesis. Schematics of the GC reaction and its 
relationship with major molecular subtypes of DLBCL. The most common shared and 
subtype-specific genetic alterations are shown, with color codes indicating the involved 
biological pathway. Blue, loss of function; red, gain of function. (Pasqualucci and Dalla-
Favera, 2015) 
 
Prognosis 
The standards for disease prognosis developed from earlier advancements because of the 
greatly heterogeneous nature of the disease. Identified significant risk factors, forming 
the basis for the International prognostic index (IPI), were further classified to form the 
Follicular Lymphoma International Prognostic Index (FLIPI). This criteria takes into 
consideration a patient’s age, clinical stage, lactate dehydrogenase levels, number of 
extranodal sites, and performance status to be able to better classify patients (Solal-
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 Celigny et al., 2004).  It was also very important to develop general criteria that relate to 
identifying B cell lymphomas on a molecular level.  
Detecting disease attributed to bone marrow in DLBCL is of vital importance for 
assessing prognosis. Marrow involvement is determined by analyzing smears obtained 
from patient samples by calculating a percentage of infiltration. Higher percentages 
indicate crowding of malignant cells and gradually inhibiting the formation of new 
hematopoietic cells, causing the typical signs of thrombocytopenia and lymphocytopenia.  
The advent of positron emission tomography to assess metabolic activity through F-
fluorodeoxyglucose (FDG) uptake was a major breakthrough for visualizing lymphocyte 
proliferation and malignancy. PET/CT scans can reveal lesion locations, mean FDG 
uptake in metabolically active cells, and lesion dimensions, all important in monitoring 
the progression of lymphoma.  
Lymphomas associated with older age (≥ 60), extranodal involvement, male sex, 
increased LDH as well as serum β2 microglobulin levels, poor performance status, and 
low hemoglobin levels are associated with poor clinical outcome. Studies have 
demonstrated these factors to contribute to a significantly lower survival rate than their 
counterparts (Solal-Celigny et al., 2004): 
10 
  
 
Figure 4- Progression-free survival of patients receiving treatment with eight cycles 
of CHOP* alone according to the number of modified IPI risk factors. 
*CHOP-(combination chemotherapy consisting of cyclophosphamide, 
doxorubicin, vincristine, prednisone) (Miller et al., 1998). 
 
Figure 4 demonstrates the importance of assessing clinical risk factors in determining 
prognosis. As seen from the graph, increased numbers of risk factors correlate with a 
lower percentage of progression free survival rates. Unfortunately, many patients exhibit 
symptoms of NHL at this time and so dose related toxicity is an important determinant in 
deciding administration of the current available therapeutic treatments. 
11 
 Specific objectives 
 
1. Provide a systematic literature review of historical/available chemotherapy 
treatment and immunotherapy for DLBCL and FL 
2. Analyze data on current investigational treatments, including phase 1 drug 
trials of Immunomodulatory drugs, kinase inhibitors, cytokine inhibitors, 
epigenetic modifiers like histone deacetylase inhibitors, 
monoclonal/bispecific antibodies and gene therapy 
3. Draw a conclusion on the validity of future DLBCL and FL treatment 
plans, such as DNA vector immunization and synthetic lethality, 
according to present data. 
4. Discuss the implications of genomic sequencing and expression mapping 
of applicable genes in B-cell malignancies. 
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 TREATMENT OPTIONS 
Chemotherapy 
With the newly discovered application of chemotherapy drugs through monitoring 
alkylating agent effects during WWII chemical warfare, drugs like chlorambucil were 
used to care for many NHL patients during the 1960s (Lakhtakia and Burney, 2015). 
Standard anthracycline based regimens grew in popularity during this time.  Since then, 
newer drugs and combination therapies have been sought after, concocted, and tested to 
observe their toxicity in conjunction to cancer fighting abilities.       
The goal of chemotherapy is to provide curative or neoadjuvant treatments by eradicating 
the patient’s store of malignant B-cells. The administration of hematopoietic regulatory 
drugs is then used to replenish the destroyed B-cells with normal functioning cells, with 
or without autologous marrow transplant. 
Many chemotherapy agents act by interacting with histone or chromatin function, to 
dysregulate active cell function and trigger cell destruction, while some agents disrupt the 
interplay of apoptotic and anti-apoptotic proteins. These chemicals achieve their function 
by binding to intracellular receptors or regulatory proteins, such as Bcl-2, and molecules 
inducing cytochrome c release (Nicholson, 2000). Molecules with high affinity for this 
protein bind the cleft, preventing the Bcl-2 from performing its inhibiting function in 
tumor cells. For this reason, Bcl-2 positive lymphomas react much better to these agents 
than non-Bcl-2 positive lymphomas. Others yet can induce expression of death receptor 
ligands, such as FasL. The Fas ligand is a CD95 transmembrane protein that is associated 
13 
 with induced apoptosis when bound to its receptor (Mullauer et al., 1998). Figure 5 is a 
schematic depicting the internal and external activation of apoptosis.  
 
Figure 5. Schematic diagram of two pathways of caspase activation. One pathway 
begins with Fas, and the other with the release of cytochrome c from the mitochondria 
(Kaufmann and Earnshaw, 2000). 
 
The activation of Fas or the release of cytochrome c promote a cascade that leads to 
cellular apoptosis. Many drugs and immunoregulators take advantage of this depicted 
process. 
The implementation of CHOP, which is a FDA approved steroid targeted chemotherapy 
combination drug consisting of cyclophosphamide, doxorubicin hydrochloride, 
vincristine sulfate (formerly oncovin), and prednisone have promoted effective remission 
of newly diagnosed DLBCL in conjunction with field radiation.  
14 
 Cyclophosphamide acts on DNA to form cross links between guanine residues, leading to 
permanent inactivation of DNA dependent function and cell destruction (Hall and Tilby, 
1992). Doxorubicin is a topoisomerase II inhibitor, acting to prevent the release of 
supercoils necessary for the interaction of transcription proteins on single stranded DNA 
(Pommier et al., 2010). Vincristine sulfate acts as a microtubulin inhibitor, interfering 
with cellular proliferation during the chromosomal separation phase of mitosis (Jordan, 
2002). 
Since its inception, the treatment has become the standard of care and first line treatment 
for many cancers. High-dose CHOP chemotherapy in conjunction with autologous stem 
cell transplant was demonstrated to cure about 50% of patients undergoing this treatment 
(Lakhatakia and Burney, 2015). CHOP alone was able to improve overall survival (OS) 
past several years, but it was recognized that ABC-DLBCL was much less responsive to 
this regimen than GCB-DLBCL. It was noted, relatively soon after, that tumor cells of 
patients with relapsed disease were essentially CHOP-resistant and were fatal without 
autologous marrow transplantation.  
Bendamustine hydrochloride is a newer chemotherapy alkylating medication that has 
demonstrated effective therapy for relapsed and indolent FL (Weidmann et al., 2002). 
The treatment with bendamustine alone in rituximab-refractory, predominantly stage 
III/IV patients produced a 75-77% ORR (15% complete response, 19% unconfirmed 
complete response, and 43% partial) (Freidberg et al., 2008). 
Other chemotherapy treatments include carboplatin, cisplatin, cytarabine, etoposide, 
gemcitabine, ifosfamide, methotrexate, mitoxantrone, oxaliplatin, procarbazine, and 
15 
 fludarabine phosphate for NHL. These agents demonstrate mechanisms of action similar 
to CHOP agents, but may induce more severe adverse reaction during the course of their 
administration. For this reason, they may typically be used in salvage therapies in patients 
with relapsed disease due to drug resistance. 
The drawbacks of chemotherapy are many. The drugs used in this process are systemic, 
either administered into circulation intravenously or orally, and not cell specific, in turn 
causing destruction of normal, healthy cells along with malignant tissue. This causes 
numerous side effects such as fatigue, anemia, hair loss, appetite changes, nausea, 
vomiting, and/or constipation (Cancer.org). Treatment with chemotherapy can induce 
oral mucositis, thrombocytopenia which causes easier bruising and bleeding, as well as a 
lowered white blood cell count leaving the patient prone to infections and febrile 
neutropenia (FN) (Aapro et al., 2011), which is a potentially life-threatening 
complication. 
High-dose treatment may also promote formation of new malignancies by inducing new 
mutations. Alkylating agents interfere with normal cell function by cross-linking DNA 
strands, causing miscoding during replication, if at all possible. This mainly affects cells 
that are actively replicating, such as the bone marrow, hair follicles, and GI epithelium, 
leading to side-effects as mentioned previously. Due to this, chemotherapy treatments 
have a high probability of causing acute myeloid leukemia (AML) in patients undergoing 
such a regimen (Vega-Stromberg, 2003). Anthracycline based drugs disrupt DNA and 
RNA synthesis, promoting similar side effects and risks for secondary malignancies as 
well (Gewirtz, 1999).  
16 
 Corticosteroid agents usually have to be administered to curb the systematic 
inflammation caused by the chemotherapy treatment cycles. This is the reason prednisone 
is administered with the combination therapy CHOP. Aside from the hazardous nature of 
the chemical agents, the concoction of these drugs becomes quite costly when patients 
undergo many cycles of treatment and/ or further salvage therapies are required. 
 
Immunotherapy 
Still more recently, a chimeric monoclonal antibody called rituximab was approved for 
use in 1997, and is now on The World Health Organization’s (WHO) list of essential 
medicines (World Health Organization, 2015). Rituximab, branded as Rituxan, is an anti-
CD20 mAb that proved to be effective at reducing malignant B-cell proliferation. CD20 
is a unique surface B-lymphocyte epitope, expressed on almost every stage of B cell 
development, encoded by q12-q13 on chromosome 11 of the MS4A1 gene (Khademi et 
al., 2017). As discussed in the diagnostic criteria, it is an excellent way to assess 
lymphoma types, especially differentiating from T-cell lymphoma. CD20 is expressed on 
all mature B cells, both normal and malignant, but not immature stem or plasma cells 
(Figure 1). For this reason, it became the target of numerous mAb treatments to destroy 
malignant B-cells.  According to prior studies, patients treated with the addition of this 
mAb drug have a 3-year event free survival rate as compared to combination 
chemotherapy alone (Pfreundschuh et al., 2006).  
The action of rituximab has been linked to inhibition of 5 main cell proliferative 
pathways: NF-κB, PI3K/AKT/mTORC1, STAT3, MEK/ERK and p38-MAPK, mediating 
17 
 a down regulation of the expression of BCL2, while activating FAS-mediated apoptosis 
(Camicia et al., 2015). A paper from 2013 by Avivi et al. describes how the anti-CD20 
antibody induces B-cell apoptosis in one of a three various mechanisms of action: 
complement dependent cytotoxicity (CDC), antibody dependent cell mediated 
cytotoxicity (ADCC) and direct anti-tumor cell activity (Aviv et al., 2013).  
CDC triggering activates a cascade of complement proteins that induces cysteine-aspartic 
proteases, cysteine aspartases or cysteine-dependent aspartate-directed proteases 
(caspases) within the cell or mitochondria to undergo apoptosis or necroptosis, similar to 
activation by FasL. ADCC is accomplished by cells carrying vesicles of perforin, which 
when released from effector cells create a transmembrane pore, disrupts electrochemical 
gradients, and causes the target cell to lyse. ADCC has a slight secondary advantage. 
When the cells lyse and release intracellular antigenic material, phagocytic antigen 
presenting cells such as the natural killer cell (NK) and macrophages engulf this newly 
dumped matrix. The cells then process the matter and are able to present it on their MHC 
surface receptors to cytotoxic T cells to promote cell induced apoptosis. The final method 
involves triggering an internal signaling cascade that activates antiproliferative 
modalities, releasing cytokines to signal dangers to nearby cells and induce self-
destruction (Avivi et al., 2013). 
Other mAbs born from this immunotherapy mediated era include obinutuzumab, 
ocrelizumab, veltuzumab, and tositumomab, classified as either type I or type II mAbs. 
Type I mAbs such as rituximab cause conglomeration of membrane CD20 receptors into 
lipid rafts, promoting death primarily by CDC and ADCC. Type II such as obinutuzumab 
18 
 on the other hand, lead more often to ADCC and direct anti-tumor induced apoptosis by 
cross-linking. In this case, cell lysis is induced via actin dependent lysosome mediated 
pathways (Avivi, et al., 2013). Anti-CD20 mAbs are effective in providing remission in 
DLBCL, FL, and chronic lymphocytic leukemia (CLL). Table 4 lists the different types 
of mAbs currently available as well as their observed contribution to various forms of 
apoptosis:  
Table 4. Current Anti CD20 antibodies and their contribution to mode of induced 
apoptosis (Avivi, et al., 2013) 
 
 
Rituximab fully depends on the binding of the γ chain of surface Fcγ receptors (FcγRs) 
expressed on immune cells including macrophages, NK cells, and neutrophils, to achieve 
its result (Clynes et al., 2000). Various studies have reported that patients with higher 
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 affinity allelic variations in the γ chain have a significantly better response to rituximab 
treatment (Cartron et al., 2002). FcγRs binding can induce either a activating or inhibiting 
effect on the cell to induce phagocytosis of CD20 positive tumor cells or activation of 
ADCC (Borossand and Leusen, 2012), opsonized by mAbs, and it was shown that 
knockout of the γ chain rendered the mAb therapy useless (Clynes et al., 2000).  
With CDC being rituximab’s primary mode of action, the interplay of complement 
proteins and rituximab was analyzed and determined that many factors influence the 
effect of complement proteins on cell destruction. It is speculated that a depletion of these 
proteins after treatment with rituximab cycles may lead to a diminished effect. A study by 
Li et al., demonstrated that depositions of complements proteins actually increased 
rituximab clearance rate (Li et al., 2007). Shortly after discovering this, a more effective 
anti-CD20 type II mAb has been glycoengineered to target FcγRs, inducing a more potent 
effect for patients experiencing relapsed or refractory NHL, especially FL (Borossand 
and Leusen, 2012). Studies have also determined that type II mAb action is superior to 
type I lipid raft CD20 formation because they induce less CD20 internalization (Beers et 
al., 2010). 
Though generally limited in its toxicity, rituximab has been reported to increase the risk 
of infections in patients undergoing a systemic treatment regimen. This might generally 
be expected, as wiping out populations of potential antibody producing B cells can cause 
a decrease in B-cell mediated humoral immunity, leaving the subject prone to bacterial 
and viral infections. It has been noted that rituximab has effects that go beyond B-cell 
destruction, with a more prominent suppression of T cell induction following dosing. 
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 (Lakhatakia and Burney, 2015) The common side effects include low white blood cell 
counts, nausea, vomiting, and mouth sores. 
 
 
NEED FOR NEW TREATMENT 
Worldwide, the prevalence of NHL has been increasing predictably. Even with the 
combination R-CHOP treatment, about one third of patients still experience a relapsed or 
refractory disease. Many can develop a rituximab resistant lymphoma, by down 
regulating CD20 expression and up regulating Bcl-xL with a very small chance at being 
cured (Jazirehi et al., 2007).  There are three ways that a patient may develop drug 
resistance: intrinsic genetic resistance, treatment acquired resistance, or tumor 
microenvironment (TME)/cell adhesion-mediated drug resistance (Camicia et al., 2015).  
Progressive recurrent translocations may lead to an alteration of the DLBCL genome, 
providing drug resistance through mutation. Treatment with prior chemotherapy, 
combined with an epigenetic variance of tumor cells may produce cells that are resistant 
tumor clones. Diseases identified as in remission may relapse strongly as a result.  
Bone marrow serves as a protective environment for both undifferentiated stem cells and 
malignant cancer cells. This so called environment mediated resistance is due to the 
presence of a plethora of soluble cell derived growth factors that induce cell proliferation 
and extracellular matrix adhesion to escape the effects of therapy (Meads et al., 2008). 
These protectant factors lead to a measurable occurrence known as minimal residual 
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disease in lymphoma patients. Current treatment methods, while improving, are still poor 
at targeting cancerous cells exclusively. 
Due to the heterogeneous nature of the disease, it is of vital importance to assess patients 
who may be resistant to certain therapies or excellent candidates for others. This concept 
points to a shift towards more personalized and precise medicine, catered to each 
individual or a small group. With technologic advances in genomic sequencing setting 
the stage for new patient specific innovations, protocols are being developed to 
incorporate disease specific genetic profiling. 
There are many drugs currently undergoing clinical trials for the treatment of DLBCL. 
Table 5 is a compiled list of drugs in various stages of testing from four different sources: 
 
Table 5. Approved novel drugs for treatment of B-lymphoid malignancies that are 
currently in clinical evaluation for the treatment of DLBCL. 
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Drug name Target/Pathway Manufacturer Approved for the 
treatment of 
Ofatumumab 
(Arzerra) Second-
generation anti-CD20 
mAb 
(↓) CD20-pro-survival 
signaling 
GSK Genmab B-cell chronic 
lymphocytic 
leukemia 
Obinutuzumab 
(Gazyva/GA101) 
Third-generation anti-
CD20 mAb 
(↓) CD20-pro-survival 
signaling 
Roche Pharmaceuticals B-cell chronic 
lymphocytic 
leukemia, FL 
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Ibrutinib 
(Imbruvica/PCI-32765) 
BTK inhibitor 
(↓) BTK, BCR/NF-
κB-pro-survival 
signaling 
Pharmacyclics/Janssen 
Pharmaceutica 
Mantle cell 
lymphoma, B-cell 
chronic lymphocytic 
leukemia, 
Waldenstrom's 
macroglobulinemia 
Lenalidomide 
(Revlimid) 
Immunomodulatory 
drug 
(↓) IRF4, BCR/NF-
κB-pro-survival 
signaling (↑) pro-
apoptotic STAT2- 
IFNα/β axis 
Celgene Multiple myeloma, 
Mantle cell 
lymphoma 
Bortezomib (Velcade) 
Proteasome Inhibitor 
(↓) NF-κB-pro-
survival signaling 
Millennium 
Pharmaceuticals 
Multiple myeloma, 
Mantle cell 
lymphoma 
Carfilzomib (Kyprolis) 
Proteasome Inhibitor 
(↓) NF-κB-pro-
survival signaling 
 Multiple myeloma 
Idelalisib 
(Zydelig/CAL-101, GS 
1101) PI3Kδ inhibitor 
(↓) PI3Kδ 
PI3K/AKT/mTORC1 
pathway 
Gilead Sciences Inc. B-cell chronic 
lymphocytic 
leukemia, Small 
lymphocytic 
lymphoma, 
Follicular lymphoma 
Dasatinib SRC kinase 
inhibitor 
(↓) SRC family 
BCR/NF-κB-pro-
survival signaling 
Bristol-Myers Squibb Chronic myeloid 
leukemia 
Brentuximab vedotin 
(Adcetris/SGN-35) 
(↓) Tubulin 
(↑) pro-apoptotic 
signaling 
Seattle 
Genetics Inc. 
Hodgkin’s 
lymphoma 
B and T-acute 
lymphoblastic 
leukemia 
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Antibody-drug 
conjugate (ADC) (anti-
CD30 mAb conjugated 
to cytotoxin MMAE) 
(MMAE is a 
microtubule disrupting 
agent) 
 Anaplastic 
lymphoma kinase-
positive large B-cell 
lymphoma 
Panobinostat 
(LBH589) HDAC 
inhibitor 
(↓) HDAC, c-MYC 
pro-survival signaling 
Novartis 
Pharmaceuticals 
Multiple myeloma 
Alemtuzumab 
(Campath-1H/LDP-03) 
Anti-CD52 mAB 
(↓) CD52-pro-survival 
signaling 
Sanofi B-cell chronic 
lymphocytic 
leukemia 
Selinexor (KPT-330) XPo1 antagonist Karyopharm  
Pembrolizumab 
(Keytruda)- PD-1 
receptor 
Inhibition of PD-1, 
allowing immune 
system to attack 
cancer cells 
Merck Melanoma 
 
MLN8237 (Alisertib) Aurora A inhibitor Takeda  
INCB24360 
(Epacadostat) 
IDO1 inhibitor Incyte  
Pinatuzumab Vedotin-
ADC 
Anti CD22 Genentech/Roche  
DCDS0780A    
SGN-CD19B- ADC Anti CD19 Seattle Genetics Inc.  
INCB050465  PI3K-Delta inhibitor Incyte  
LAM-002A (apilimod 
dimesylate) 
PIKfyve kinase 
inhibitor 
LAM  
MPDL3280A  Anti PDL1 Roche  
Ipilimumab (Yervoy) Anti CTLA-4 Bristol-Myers Squibb Melanoma 
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Obtained from Caicia R, Winkler HC, Hassa PO, 2015 and updated with information 
from cancer.gov, mycancergenome.org, and clinicaltrials.gov. mAB monoclonal antibody, 
BTK Bruton’s tyrosine kinase, BCR B cell receptor, NF-κB nuclear factor-kappa B, IRF4 
interferon-regulatory factor 4, STAT2 signal transducer and activator of transcription 2, 
IFNα/β interferon alpha/beta, PI3K phosphoinositide 3-kinase, mTORC1, mammalian 
target of rapamycin (mTOR) complex 1, HDAC histone deacetylase 
 
Nivolumab (Opdivo)-
IgG4 
Anti PDL1 Bristol-Myers Squibb HL, Melanoma, 
non-small cell lung 
cancer, renal cell 
carcinoma 
Everolimus (Afinitor) mTOR inhibitor Novartis 
Pharmaceuticals 
Breast, pancreatic, 
gastrointestinal, lung 
(certain types), renal 
cell carcinoma, 
subependymal giant 
cell astrocytoma  
Pixantrone (Pixuvri) Topoisomerase II 
inhibitor and 
intercalating agent 
CTI Biopharma  
Vorinostat (Zolinza)- 
suberanilohydroxamic 
acid 
Histone deacetylase 
inhibitor 
Merck Cutaneous T-cell 
lymphoma 
Polatuzumab vedotin 
with MMAE-ADC  
Anti CD79B   
Blinatumomab-BsAbs Anti-CD3 and Anti-
CD19 
Amgen Philadelphia 
chromosome 
negative ALL 
Aabexinostat-HDAC 
inhibitor 
(↓) HDAC, c-MYC 
pro-survival signaling 
Pharmacyclics LLC  
Belinostat (beleodaq)-
HDAC inhibitor 
(↓) HDAC, c-MYC 
pro-survival signaling 
TopoTarget Peripheral T-cell 
lymphoma 
Venetoclax BCL2 inhibitor Genentech CLL (17p deletion) 
Obtained from Caicia R, Winkler HC, Hassa PO, 2015 and updated with information from 
cancer.gov, mycancergenome.org, and clinicaltrials.gov. mAB monoclonal antibody, BTK 
Bruton’s tyrosine kinase, BCR B cell receptor, NF-κB nuclear factor-kappa B, IRF4 interferon-
regulatory factor 4, STAT2 signal transducer and activator of transcription 2, IFNα/β interferon 
alpha/beta, PI3K phosphoinositide 3-kinase, mTORC1, mammalian target of rapamy in (mTOR) 
complex 1, HDAC histone deacetylase 
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 There are many trials assessing combination therapies of two or more of these drugs, to 
interact with pathways at least two checkpoints, as well as their efficacy when added to 
current mAb or chemotherapy schedules. 
Pixantrone is a novel topoisomerase II inhibitor that was synthesized to exhibit limited 
cardiotoxicity effects when compared to the long term anthracycline effects of 
doxorubicin. Trials are currently in the third phase, investigating pixantrone as a potential 
replacement for doxorubicin in the CHOP therapy schedule. As a single agent salvage 
therapy in pretreated patients with replaced or refractory NHL, pixantrone has proven to 
be effective with tolerable adverse reactions (Pettengell et al., 2012). 
Bendamustine treatment has been combined with obinutuzumab to test the efficacy of the 
treatment for rituximab refractory indolent NHL, gauged by the Functional Assessment 
of Cancer Treat-lymphoma questionnaire (FACT-Lym). Bendamustine demonstrated a 
77% response rate, while treatment with combined bendamustine and obinutuzumab (G-
B arm) achieved an increased progression free survival (PFS) over standard care with 
bendamustine alone (Cheson et al. 2017). This treatment also scored higher in the patient 
quality of life assessment, only 1-3 points lower than a disease-free NHL population.  
To combat the effects of systemic toxicity, antibody-drug conjugates are being developed 
to direct cytotoxins to specific targets. Polatuzumab vedotin and pinatuzumab vedotin are 
two such examples comprising an anti-CD79B and anti-CD22 antibody respectively 
conjugated to mono methyl auristatin E (MMAE), a cytotoxic agent. 
The conjugated antibody exhibits its effect by attaching to the targeted surface receptor, 
being internalized and activating via lysosomal degradation, inducing its intercalating 
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effect intracellularly. This strategy allows specific guidance of potent cytotoxity agents 
exclusively into directly selected cell types, illustrated in figure 6: 
Figure 6. Mechanism of action of CMC-544. CMC-544 is an anti-CD22 ADC 
(inotuzumab ozogamicin-calicheamicin) that shows promise for relapsed B-ALL but has 
been discontinued at phase III in 2013 as a treatment for NHL according to Pfizer. 
Figure used to illustrate mechanism of action of anti-body drug conjugation (Thota and 
Advani, 2017). 
 
 
 
Polatuzumab vedotin and pinatuzumab vedotin have demonstrated high activity and 
toxicity to B-cells in DLBCL in early trails. Both ABC and GCB subtypes responded 
positively to these treatments, even with low target expression and target mutation 
(Pfeifer et al., 2015). 
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 Programmed death-1 (PD1) and cytotoxic T-lymphocyte antigen (CTLA-4) serve as 
immune checkpoints, or negative regulators, protecting against autoimmune reactions by 
suppressing cytotoxic T-cell activation when bound with PDL1 and ligand B7 
respectively. Inhibitors, like nivolumab, MPDL3280A, and pembrolizumab, are being 
investigated for their use in modulating T-cell activation and response. PDL1 is heavily 
unregulated in cancer cells, providing a means of immune system escape. Pembrolizumab 
inhibits this receptor, while nivolumab and MPDL3280A block the ligand from achieving 
its intended result, thus removing the brakes from cell mediated apoptosis, allowing 
cytotoxic T-cells to attack malignant tumor cells (Carbognin et al. 2015).  
Ipilimumab is an anti-CTLA-4 mAb being investigated for treatment in relapsed and 
refractory B-cell NHL. Current phase I trials have determined treatment with ipilimumab 
to be well tolerated at increasing dose levels. Out of eighteen patients treated, 2 had a 
clinical response. A DLBCL patient experienced ongoing complete response for over 31 
months, and a FL patient demonstrated a partial response lasting 19 months (Ansell et al., 
2009), showing potential as an anti-tumor treatment for NHL patients. 
Epigenetic drugs, largely part of the histone deacetylase inhibitors, have made their way 
into clinical trials for B-cell lymphomas. Abexinostat is an orally administered histone 
deacetylase inhibitor which has shown potential in treatment of T-cell malignancies. It is 
currently being tested in phase II for patients with relapsed or refractory NHL. The 
results of this trial showed a ORR of 28% (5% CR), with the highest response observed 
in FL patients at 56% (Ribrag et al., 2017). While showing promise in B-cell lymphoma 
treatment, this drug was likely related to various grade 3 and higher adverse events in 
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 88% of patients, such as thrombocytopenia, neutropenia, as well as anemia. Other HDAC 
inhibitors include vorinostat, and panobinostat, which are also being tested for their 
efficacy in treatment of lymphoma. 
Reversible proteasome inhibitors such as bortezomib, carfilzomib, and ixazomib are 
being used to induce enough cell stress to promote apoptosis in DLBCL subtypes with 
constitutive NF-κB activation. Nuclear factor-κB activation signals the expression of 
genes that through transcription promote cell angiogensis and antiapoptosis. This 
perpetual activation also promotes cell invasiveness and metastasis by allowing cells to 
survive outside of their original tissue. Proteasome inhibitors demonstrated to have a 
multifocal effect on this pathway and many others to promote malignant cell death. It is 
also capable of killing B-cells through caspase-independent mechanisms. 
Table 6. Proteasome inhibitor class mechanism of action (Bose et al., 2014) 
*CDK inhibitors 
Mechanism of action of proteasome inhibitors  
Stabilization of p21, p27, and p53* 
Stabilization of c-Jun N-terminal kinase (JNK) 
ROS generation 
Inhibition of NF-κB activation 
Inhibition of extracellular signal-regulated kinase (ERK) signaling 
Disruption of the UPR, thereby leading to endoplasmic reticulum (ER) stress 
Interference with tumor–microenvironment interactions 
Inhibition of DNA repair 
Up regulation/activation of pro-apoptotic Bcl-2 family proteins 
Down regulation of several anti-apoptotic proteins 
Anti-angiogenic effects 
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Stabilization of the CDK inhibitors prevents the activating kinase from promoting cell 
proliferation, and simultaneous activation of pro-apoptotic proteins, that were saved from 
proteome degradation, trigger cell death. This is a very promising therapy as bortezomib 
combination with R-CHOP produced a 100% ORR for evaluable patients (n=35), and 
88% for the total (with an 86% CR rate) cohort of 40 subjects (Ruan et al., 2011). The 
toxicity analysis of this trial showed that the dose escalations adverse events were 
clinically manageable, with many patients again experiencing neuropathy, anemia, 
neutropenia, and thrombocytopenia. Unlike treatment with R-CHOP alone, this combined 
therapy including bortezomib demonstrated similar outcomes for both GCB and ABC 
subtypes of DLBCL. Bortezomib is also being combined with gemcitabine, ifosfamide, 
and cisplatin to assess therapeutic effects. MLN4924 is another targeted NF-κB inhibitor 
therapy that was shown to promote tumor regression (Milhollen et al., 2010) in a similar 
manner. 
There is an interesting concept being explored called synthetic lethality, which deals with 
the idea that two genes when mutated together cause cell death, while mutation of only 
one is conducive to life (Kaelin, 2005). Stemming from the concept of gene-gene 
interactions, selective gene targets with enzymatic products may be neutralized to 
produce a loss of function mutation. While normal cells are minimally affected due to the 
mutation of a single gene, cancerous cells earlier screened for the necessary 
complementary mutation will cease to function, and eventually undergo cell death. 
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 Synthetic lethality can be applied to chemical compounds that are selective in their 
toxicity for mutated proteins as well (Fantin and Leder, 2004). 
As discussed in prognosis, bone marrow involvement is a major risk factor in DLBCL 
and FL. One of the more important effects of BKT140, a CXCR4 inhibitor, and possibly 
other chemokine receptor inhibitors is the interference in the spread of lymphoma to a 
patient’s bone marrow as well as effectively targeting NHL that has already achieved 
marrow involvement. Not only is this a potential way to prevent disease progression and 
metastasis, but it also serves as a method to address the issue of environment-mediated 
resistance. In figure 7, we see a comparison of mice injected with BL-2 cells to produce a 
localized tumor, then treated with combinations of BKT140 and rituximab. 
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Figure 7. In vivo NHL models: BKT140 cooperation with rituximab, limiting spread to 
bone marrow, and blocks induced CXCR4 expression in local tumor cells. Both agents 
delivered subcutaneously to BL-2 bearing mice. The DAPI binds staining allows us the 
visualize the nuclei of cells. TUNEL assays demonstrate fragmented DNA. The top most 
graphs indicate concentrations of CD20+ cells in A. Bone Marrow B. Blood and C. Body 
weight gain of mice (Beider et al., 2013) 
Diamidino phenylindole (DAPI) is a fluorescent stain that emits blue light when bound to 
DNA regions rich in adenine and thymine. The fading density move from left to right 
along the DAPI stain indicate the presence of fewer cells each time. TUNEL, on the other 
hand, is a molecular probe that binds 3’ hydroxyl ends of broken strands of DNA, 
essentially indicating ongoing apoptosis. The dense color moving from left to right 
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 demonstrates the presence of fragmented euchromatin. The fluorescent analysis confirms 
the assertion that this combination treatment reduced tumor mass and blocks the effect of 
CXCR4 expression in NHL cells. The effects are remarkable and show great efficacy 
applications in bone marrow and blood of tested mice population. Further 
experimentation should be done, as the suggestions indicate a possible and effective 
interaction of CD20 and the CXCR4 pathways in NHL. 
Inhibiting chemokine receptors that are involved in the cells compartmental movement 
has shown to result in a significant inhibition of lymphoma cell growth. The CXCR4-
CXCL12 serves as an important axis in the hematopoietic proliferation. BKT140 is a 
CXCR4 antagonist that seems to also cooperatively influence cell apoptosis with 
rituximab (Beider et al., 2013). Interestingly, rituximab increases CXCR4 expression in 
cells. BKT140 counteracts this observation, inhibiting tumor progression.  If a CXCR4 
modulating effect can be achieved in vivo, there is hope that rituximab will prove to be 
more effective in treating malignant lymphomas. 
Antibodies have a relatively short half-life, varying on the order of hours to days. This 
generates the need to reinfuse patients undergoing antibody therapies or provide a 
constant source of external antibodies, proving to be a very resource heavy treatment 
plan. DNA immunization and gene therapy is currently being investigated as a promising 
longer term solution. DNA vectors encoding bispecific antibodies or anti-CD20 
antibodies have been shown to be effective in mediating the death of multiple b-cell 
lymphoma cell lines. Injecting an engineered vector into an appropriate cell will enable 
the production of cell derived antibodies for a much longer period of time. CD20 cDNA, 
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 encoding proteins with post-transcriptional modifications, can be injected into cells using 
electroporation to produce viable anti-CD20 antibodies against the extracellular CD20 
epitope (Khademi et al., 2017).  
Methods of injecting cDNA, to generate hybridoma cell lines capable of producing 
antibodies against a certain epitope, are being tested. Anti-CD20 antibodies produced in 
mice populations by hybridoma cells were analyzed for human compatibility via ELISA 
assay and were shown to bind native CD20 on B lymphocytes (Khademi et al., 2016). 
This method allows the opportunity to generate mAbs with affinities for different CD20 
epitopes, producing antibodies with similar end effects but more desirable characteristics. 
The methods from this study used naked plasmid DNA that can potentially be used as a 
gene therapy. 
Antibodies can also be engineering to act as bispecific antibodies (BsAbs) causing an 
interlinking of two antigens. Binding cancerous epitopes with T-cells, in turn could 
provoke T-cell mediated apoptosis by perforin and granzyme release. In a paper 
published by Pang et al., in 2016, it was hypothesized that using this method, any CD3 
positive T-cell can be recruited to attacked a specific epitope target. Temporary B-cell 
apoptosis can be induced to occur with an anti-CD20 x anti-CD3 diabody, linking B and 
cytotoxic T-cells. If not spread to bone marrow, there is a chance such a regimen could 
result in elimination of malignant B-cells in lymph tissue and circulation. Through 
intravenous injection of human T-lymphocytes, this investigational treatment can be seen 
as a targeted cell mediated chemotherapy, with antibody vectors (Pang et al., 2016). 
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 Blinatumomab is an example of one such BsAbs binding to CD3 receptors of T-cells and 
CD-19 receptors of B-cells.  
According to a 2016 study by Goebeler et al., treatment with Blinatumomab resulted in 
antilymphoma activity with stable complete response (CR) or partial response (PR), with 
an overall response rate of 69%. The adverse reactions noted in this phase I study were 
increased pro inflammatory cytokines, flu-like symptoms, hypogammaglobulinemia and 
neurologic events, associated with the mode of action of the treatment. The resulting 
hypogammaglobulinemia left patients prone to infections, and there were two infection 
related deaths, possibly related to this treatment (Goebeler et al., 2016). 
B-cell MHCII receptors can be targeted in a similar fashion. B-lymphoma development 
has been associated with bacterial and viral cytogenetic vectors. EBV, Helicobacter 
pylori, and hepatitis C infection causing prolonged B-cell proliferation has been noted to 
induce B-cell lymphoma (Haabeth et al., 2014). Targeting MCHIIs on not only B-cells, 
but other antigen presenting cells (APCs), can serve as a way to suppress this response to 
avoid development of not only B-cell lymphomas, but autoimmune reactions. CD4+ 
cytotoxic T-cells can also be reciprocally activated by APCs to target malignant tumor 
cells. 
The discovery of Immunomodulatory drugs (IMD) paved the way of novel thinking about 
drug action, where rather than inhibiting an enzyme, IMDs (originally Thalidomide) 
regulate levels of enzyme activity and in turn regulate levels of interleukins or interferons 
(Kotla,et al., 2009). Thalidomide at its conception faced much backlash due to its 
teratogenic role in embryo development. After further research, analogues such as 
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 lenalidomide and pomalidomide surfaced, proving to be quite effective in their potency 
against malignancies. Lenalidomide works through many pharmacodynamic pathways, 
altering cytokine production, inducing T-cell co-stimulation and modulating Natural 
Killer cell functions shown in figure 8:  
 
Figure 8. Immunomodulatory effects of Lenalidomide on various cells (Kotla et al., 
2009). 
 
Highly elevated tumor necrosis factor alpha levels (TNF-α) have been implicated in 
hematologic disorders, rendering the proliferation of hematopoietic stem cell ineffective 
and possibly causing them to undergo apoptosis (Symeonidis et al., 1991). Lenolidamide 
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 demonstrates protective factors by reducing TNF-α at least one-thousand fold greater 
than thalidomide, correlating with a reduction in tumor size in a relatively short time 
period (Muller et al., 1999). It does not in itself induce a direct cytotoxic effect though. 
By suppressing the production of proinflammatory cytokines lenalidomide demonstrates 
protective factors for hematopoietic cells and activates others. 
The compound acts on inducing T-cell costimulation by phosphorylating CD28, 
triggering clonal T and NK cell proliferation (Corral et al., 1999). By accomplishing this, 
lenalidomide can be used in conjunction with another T-cell mobilizing treats , such as 
blinatumomab, to induce a potent immune therapy, while NK cells can provide cell 
mediated ADCC. 
Tumor cells have been identified in their excellent capability of generating new blood 
supply to supplement their metabolic need for growth. Many antiangiogenic drugs are 
ineffective at targeting tumors centrally as single agents because, as blood vessels 
degrade peripherally, the drug can no longer be delivered effectively, yet lenalidomide 
has antiangiogenic properties that may slow the growth of solid tumors in lymphoma by 
decreasing the expression of angiogenic factors like VEGF. It can also induce a direct 
anti-tumor effect by up regulating CDK inhibitors like p21, increasing Fas mediated 
apoptosis, and inferring growth arrests (Kotla et al., 2009). 
Phosphatidylinositol 3-kinase (PI3K) contains 4 isoforms that have a role in a variety of 
different pathways relating to survival and proliferation activated by growth factors. 
PI3Kδ mutations are preferentially responsible for hematological malignancies (Curran 
and Smith, 2015).  Idelalisib and INCB050465 are both PI3Kδ inhibitors, which results in 
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 a decreased phosphorylation of Akt, inducing cell apoptosis. Phase II trials demonstrated 
a 57% response rate with idelalisib alone for relapsed or refractory previously treated 
NHL patients.  
Further downstream, Everolimus is another investigation drug for DLBCL that functions 
to inhibit mTOR as a rapamycin analog. A phase II study demonstrated an overall 
response of 30% with Everolimus alone, and 38% when added to rituximab (15% CR) 
(Merli et al. 2015). 
Future direction 
With recent gene expression profiling and consensus clustering, the existence of other 
subsets of DLBCL, not currently specified, have been distinctly grouped. According to 
Stefano et al., target RNA was prepared from a random selection of 17 out of 176 
DLBCL patients with viable tumor cells and hybridized to microarrays to analyze 
patterns. Following analysis, there were three discrete subsets of DLBCL identified 
coined oxidative phosphorylation, B-cell receptor proliferation, and host response. 
The oxidative phosphorylation cluster was determined to contain higher levels of 
antiapoptotic BCL2 and proteasome 26s components. B-cell receptor proliferative 
clusters contained high concentrations of cell-cycle regulator proteins, expressing 
increased DNA repair mechanisms, and many components used in the B-cell receptor 
signaling cascade. Host response based DLBCL focused primarily on expressing T-cell 
receptor components, higher levels of cytokine release, increased adhesion molecules, 
and TNF ligands. Interestingly, each cluster had a similar survival rate from patient to 
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 patient identified at 54% for host response, 60% for B-cell proliferative, and 53% 
oxidative phosphorylation (Stefano et al. 2005)  
Studies like that of Stefano, et al. (2005) continue to demonstrate the importance of 
genetic profiling in medicine. With the understanding of each malignancy and the main 
underlying causes, appropriate medications may be administered. The heterogeneity of 
DLBCL is extensive, with ABC and GBC subtypes offering an even larger variety of 
possible targets.  In the case of the oxidative phosphorylation DLBCL cluster, down 
regulating BCL2 via NF-κB inhibiting modalities like rituximab may be best suited. 
Selective targeting of BCL2, using a small molecule inhibitor may also be effective in 
obtaining a response. Venetoclax is an inhibitor that can be used to combat the 
overexpression of BCL2 in malignant B-cells. This dysregulation is fundamental to 
DLBCL, FL and other cancerous tumor cells affecting the hematological cell line. 
Chromosomal amplification can allow assessment of the 18q21 region, responsible for 
the BCL2 up regulation (Davids et al., 2017). Venetoclax is superior to its predecessor 
navitoclax because it is not associated with dose limited adverse events of 
thrombocytopenia (Wilson et al., 2010). It is overall well tolerated with a response rate of 
38% in FL patients and 18% in DLBCL. Further trials need to be conducted to investigate 
the necessary pairing of other treatments.  Clusters identifying with host response and 
transformation via inflammatory modalities, on the other hand, may best be addressed 
using immunomodulatory drugs like lenalidomide.  
Determining oncogenic cooperativity in signaling pathways will further allow the 
creation of multi-mechanism based therapy to induced cell destruction in the entirety of 
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 the malignant cell line. Of course, many of these treatments in existence and study are not 
lymphoma specific. Cross referencing the inhibition or activation of oncogenes and tumor 
suppression genes will serve to produce more clinical trials in the battle against malignant 
lymphomas, while advances in profiling will demonstrate viable targets.  Figure 9 
demonstrates many of the above mentioned biochemical pathways, their 
interconnectivity, and molecules intended to target them in the hope of slowing or 
eliminating uncontrolled cellular growth. 
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 CONCLUSION 
 
There has been a great paradigm shift towards developing specialized treatments that can 
achieve even higher percentages of complete remission in the non-hodgkin lymphoma 
patient population. In the last decade, treatments that are less toxic, more efficient, and 
readily available have been explored. Novel agents such as lenalidomide, ibrutinib, 
bortezomib, BKT140, as well as various methods of inducing in-vivo humoral immunity, 
used as single agents or in combination therapy, demonstrate the potential to treat patients 
with relapsed disease, who previously had very little alternatives. Our methods for 
standard of care treatment are experiencing a revamping from current clinical trials that 
will prove important in assessing patient specific regimens. 
There remains a risk for developing NHL after infection with hepatitis B, hepatitis C, 
HIV, Epstein-Barr virus, or various autoimmune disorders that has been the driving force 
behind the increasing incidence rate of NHL in the last decade (Fisher and Fisher, 2004).  
The immunosuppression associated with standard treatment of autoimmune disorders and 
HIV infections opens up the possibility of acquiring the disease, seen at a rate of 1% 
annually in the general population (Rabkin and Goedert, 2017) and at a similar rate for 
patients undergoing treatment with antiretroviral therapy. While such treatments may 
provide long lasting advantages, it is important to monitor patients to promptly identify 
any infections during these periods of antibody and plasma cell depletion. This calls for a 
need to develop drugs that are even more selective for malignant B-cells and limiting in 
their viral reactivation.  
42 
 This may partially be achieved by screening for FcγR polymorphisms that may dictate 
the effectives of CD20 mAbs in patients. As the trend goes, the costs of assessing 
susceptibility to and manufacturing specific antibodies have been decreasing with 
technological advances and wide spread incorporation. Monthly drug costs upwards of 
sixty thousand dollars are limiting in their ease of use for insurers, hospital 
administration, and patients alike. It is feasible that within another decade, investigational 
drugs like the aforementioned will be an affordable standard of care for all, analogous to 
successful vaccines. 
For this to occur continuous trials are still underway to test the drugs interference with 
proliferative and antiapoptotic cellular pathways, in order to assess their relative toxicity. 
Novel discoveries, like the aforementioned medications, have pointed to many new 
modes of treatment in the past decade, especially as they relate to the hematology 
oncology realm. Before long now, there is high hope that indolent diseases like FL, and 
eventually DLBCL, will achieve cure rates closer to ninety percent, as well as stabilizing 
the prevalence of new diagnoses.  
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